A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. (Q39071313)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

S Ugurel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

C Loquai

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

K Kähler

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

J Hassel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

C Berking

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

L Zimmer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

I Haubitz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

I Satzger

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

T Müller-Brenne

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

N C Mikhaimer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

J C Becker

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

K J Kilian

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

D Schadendorf

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

L Heinzerling

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

M Kaatz

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

D Göppner

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

C Pföhler

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

A Pflugfelder

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

R Mössner

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

R Gutzmer

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Dermatologic Cooperative Oncology Group (DeCOG)

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

publication date

18 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

573-582

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25524477%20AND%20SRC:MED&resulttype=core&format=json

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

25 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Improved overall survival in melanoma with combined dabrafenib and trametinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU573